Evenity (Romosozumab) in Children Under 12: What We Know About Developmental Impact

Why Romosozumab Is Not Approved for Children Under 12

Romosozumab received FDA approval in April 2019 for postmenopausal women with osteoporosis at high fracture risk. The approval was based on adult trial data exclusively. The FDA label explicitly excludes pediatric patients, and the agency has not issued any guidance permitting use in children under 12 under any current pathway.

The absence of approval is not a regulatory technicality. It reflects a genuine gap in safety and efficacy data. Children under 12 are in active skeletal growth, and the drug's primary molecular target, sclerostin, is a growth-regulatory protein expressed throughout developing bone and cartilage.

What the FDA Label Actually Says

The prescribing information for Evenity states that safety and efficacy have not been established in pediatric patients. The label also carries a boxed warning for myocardial infarction, stroke, and cardiovascular death, based on findings from the ARCH trial. Because children with primary osteoporosis may already carry underlying systemic conditions that raise cardiovascular risk, this signal is not trivially dismissable in younger populations.

The FDA's accessdata portal for Evenity (NDA 761062) confirms no pediatric studies were submitted as part of the original approval package. [1]

Regulatory Classification of Pediatric Use

Under the Pediatric Research Equity Act (PREA), sponsors of certain new drug applications must conduct pediatric studies. Romosozumab's manufacturer was granted a partial waiver for children under 2, and the full pediatric development plan for older children had not been finalized as of the drug's 2019 approval. This means any physician administering romosozumab to a child under 12 is operating entirely outside a regulatory framework. [2]

The Biology of Sclerostin in a Developing Skeleton

To understand why romosozumab carries unique developmental risks in young children, it helps to understand what sclerostin actually does in a growing body. Sclerostin, encoded by the SOST gene on chromosome 17q21.31, is a glycoprotein secreted primarily by osteocytes. It acts as a brake on the Wnt/beta-catenin signaling pathway, which drives osteoblast activity and new bone formation. [3]

In adults, blocking sclerostin tips the balance toward bone building. In children, this same pathway is doing considerably more work.

Sclerostin's Role at the Growth Plate

Growth plates (physes) in children under 12 are metabolically active zones of endochondral ossification. Chondrocytes in the growth plate express sclerostin and respond to Wnt signaling. Research published in Bone (2014) demonstrated that Wnt pathway activation in growth plate chondrocytes alters both chondrocyte differentiation and the rate of longitudinal bone growth. Disrupting this balance pharmacologically could theoretically accelerate or distort growth plate maturation. [4]

In mouse models carrying loss-of-function SOST mutations, animals show not only increased bone mass but measurable changes in bone geometry and cortical architecture that differ from wild-type controls. Whether these structural deviations translate into functional problems during load-bearing growth in humans is unknown.

Sclerosteosis and Van Buchem Disease as Natural Experiments

Nature has provided two rare human analogs: sclerosteosis and Van Buchem disease. Both involve loss-of-function variants in the SOST gene or its regulatory region, resulting in lifelong sclerostin deficiency from birth. Patients develop progressive bone overgrowth, cranial nerve entrapment (leading to facial palsy and hearing loss in some cases), and elevated intracranial pressure. [5]

These conditions demonstrate what happens when sclerostin signaling is absent from the earliest stages of development. Romosozumab does not replicate complete SOST loss, but it does substantially suppress circulating sclerostin. In a child whose skeleton and cranium are still growing, even partial suppression of sclerostin warrants caution.

A 2020 review in the Journal of Clinical Endocrinology and Metabolism noted that the bone overgrowth phenotype in sclerosteosis patients begins in early childhood and is progressive, underscoring that sclerostin's regulatory role is not a static adult phenomenon. [6]

Cardiovascular Safety: Does the Adult Signal Matter for Children?

The most prominent safety concern in romosozumab's adult approval history is cardiovascular. The ARCH trial (N=4,093) directly compared 12 months of romosozumab followed by alendronate against alendronate alone in postmenopausal women with osteoporosis. The romosozumab-then-alendronate group showed a higher rate of serious cardiovascular events: 2.5% versus 1.9% in the alendronate-only arm, a statistically significant difference (P<0.05). [7]

This finding prompted the FDA to add a boxed warning and to specify that romosozumab should not be initiated in patients who have had a myocardial infarction or stroke within the preceding year.

Extrapolating Cardiovascular Risk to Pediatric Patients

Healthy children under 12 rarely have atherosclerotic cardiovascular disease, so the ARCH signal might seem irrelevant. However, children who present with osteoporosis severe enough to consider romosozumab often have underlying conditions, including chronic inflammatory diseases, glucocorticoid exposure, immobility disorders, or connective tissue abnormalities, that may alter baseline cardiovascular physiology. The cardiovascular risk profile of such a child should be carefully characterized before any anti-sclerostin therapy could be contemplated. No pediatric data exist to inform this risk calculation.

Bone Mineral Density Gains in Adults: Context for Pediatric Extrapolation

In the FRAME trial (N=7,180), 12 months of romosozumab 210 mg monthly produced a 13.3% increase in lumbar spine BMD and a 6.9% increase in total hip BMD compared to placebo. New vertebral fractures occurred in 0.5% of the romosozumab group versus 1.8% of placebo (relative risk reduction 73%, P<0.001). [8]

These are impressive numbers for a postmenopausal woman with established bone loss. Applying this same logic to a child, whose skeleton is actively accreting bone through puberty anyway, requires a fundamentally different benefit-risk calculus. Children with severe osteogenesis imperfecta or other bone fragility conditions may accrue bone rapidly if their underlying disease is well-managed with existing agents, making the incremental benefit of romosozumab harder to justify against its unknown developmental risks.

Neurodevelopmental Considerations

Sclerostin expression is not limited to bone. SOST gene expression has been detected in the brain, specifically in neurons of the cerebral cortex and hippocampus. [9] The functional role of neural sclerostin in humans is incompletely understood, but Wnt/beta-catenin signaling is deeply involved in synaptic development, neuronal survival, and axonal guidance during early childhood brain maturation.

The potential for romosozumab to cross the blood-brain barrier is not well characterized. As a large IgG2 monoclonal antibody with a molecular weight of approximately 136 kDa, significant central nervous system penetration is unlikely under normal physiological conditions. Still, no pediatric studies have measured cerebrospinal fluid levels or systematically assessed neurodevelopmental outcomes in children exposed to anti-sclerostin therapy.

Animal Model Data on Neural Sclerostin

A 2018 study in Scientific Reports demonstrated that SOST knockout mice show altered hippocampal neurogenesis compared to wild-type littermates. The authors concluded that endogenous sclerostin may modulate adult neurogenesis in rodents, though whether this extrapolates to pediatric human neurodevelopment is speculative at current evidence levels. [10]

The absence of evidence here is not reassurance. It is a gap that would need to be filled before any pediatric regulatory submission could be entertained.

Current Standard of Care for Pediatric Osteoporosis

Children under 12 with clinically significant osteoporosis, including those with osteogenesis imperfecta (OI), chronic glucocorticoid-induced bone loss, or immobilization, are treated with agents that have actual pediatric safety data. The Endocrine Society's 2019 clinical practice guideline on bone disease in chronic conditions notes that intravenous bisphosphonates remain the most evidence-supported pharmacological option for children with fragility fractures. [11]

Bisphosphonates as the Foundation

Pamidronate (3 mg/kg/cycle IV, cyclically) and zoledronic acid (0.05 mg/kg IV annually) have decades of use in pediatric bone disease. Long-term follow-up data from children treated with cyclical pamidronate for OI show sustained improvements in lumbar spine BMD Z-scores without evidence of growth plate disruption or long-term developmental harm when used within standard dosing protocols. [12]

Denosumab: A Closer Comparison

Denosumab (Prolia, XGEVA), another bone-active monoclonal antibody, has been used off-label in pediatric patients with giant cell tumors and OI. Post-treatment rebound hypercalcemia is a documented risk in children after denosumab discontinuation, sometimes severe enough to require hospitalization. This experience illustrates that bone-active biologics carry pediatric-specific risks not predicted by adult trial data, and the lesson applies directly to romosozumab. [13]

When Might Romosozumab Be Considered Investigationally

A small cohort of children with extremely severe OI (Sillence types III or IV) who fail multiple bisphosphonate regimens and denosumab may theoretically be candidates for experimental protocols. Any such use would require ethics board approval, fully informed parental consent, baseline cardiovascular evaluation, growth plate assessment by MRI or skeletal survey, and close monitoring of bone age every 6 months.

The following decision framework represents HealthRX's synthesis of current evidence gaps and clinical considerations for the rare scenario of investigational romosozumab in pediatric patients. It is intended as an editorial structure for physician review and is not a treatment protocol.

Pre-use requirements (investigational only, ethics board mandated):

1. Document failure of at least two bisphosphonate regimens AND denosumab
2. Obtain pediatric cardiology clearance (ECG, echocardiogram)
3. Establish baseline bone age radiograph and growth velocity over 12 months
4. Measure baseline cranial circumference and screen for signs of elevated intracranial pressure
5. Obtain neurodevelopmental baseline assessment (standardized cognitive and motor scoring)
6. Limit exposure to no more than 6 monthly doses as a starting hypothesis, pending interim safety review
7. Monitor sclerostin levels, IGF-1, and bone turnover markers (P1NP, CTX) at months 1, 3, and 6

What Juvenile Animal Studies Suggest

FDA drug development guidance for pediatric indications frequently requires juvenile animal toxicology studies when the drug may be used in children. For romosozumab, the available preclinical data in juvenile rodents showed that chronic sclerostin inhibition during active growth phases resulted in changes to cortical bone geometry. Specifically, treated animals showed wider cortical bones with altered porosity patterns compared to controls. [1]

Whether wider, denser cortical bone in a growing animal constitutes harm or benefit depends on context, and that ambiguity is itself the problem. A growing child's skeleton is not simply a small adult's skeleton. The remodeling dynamics, hormonal milieu (especially pre-pubertal IGF-1 and GH axis activity), and biomechanical loading patterns differ substantially, and none of these variables were represented in adult romosozumab trials.

Monitoring Parameters If Investigational Use Proceeds

If a child under 12 receives romosozumab under an investigational or compassionate-use framework, the following parameters should be tracked at minimum:

• Bone age (left-hand radiograph) every 6 months to detect accelerated or arrested growth plate maturation
• Height velocity plotted against CDC growth charts (cdc.gov/growthcharts) monthly
• Serum sclerostin (not yet a standard clinical assay but available through research labs)
• Bone turnover markers: P1NP (formation) and serum CTX (resorption) at baseline and every 3 months
• Cranial circumference (especially in children under 5) to screen early for excessive bone apposition at skull sutures
• Cardiovascular monitoring: blood pressure and heart rate at each visit; cardiac event reporting per MedWatch
• Neurological screening: parental and teacher behavioral questionnaires at 3-month intervals

Key Evidence Gaps That Must Be Filled

The research community has not yet answered these questions for children under 12:

1. What is the pharmacokinetic profile of romosozumab in pre-pubertal children (volume of distribution, half-life, clearance)?
2. Does sclerostin inhibition during the rapid bone accrual phase of childhood (peak bone mass acquisition, typically ages 10 to 14) result in higher or lower peak bone mass at age 25?
3. What is the rebound effect on bone turnover markers after a 12-month course in a growing skeleton?
4. Does romosozumab alter growth plate cartilage in a primate model?
5. Are there detectable effects on brain-derived neurotrophic factor (BDNF) or other neurodevelopmental markers in juvenile animals treated with anti-sclerostin antibodies?

Until these questions have peer-reviewed answers, the risk-benefit ratio for elective or routine use of romosozumab in children under 12 is not calculable. [14]